Evidence map›Paper›PMID 35625832›Full record

ArticleBiomedicines2022

IFNγ-Treated Macrophages Induce EMT through the WNT Pathway: Relevance in Crohn's Disease.

Dulce C Macias-Ceja, Sandra Coll, Cristina Bauset, Marta Seco-Cervera, Laura Gisbert-Ferrándiz, Francisco Navarro, Jesus Cosin-Roger, Sara Calatayud, María D Barrachina, Dolores Ortiz-Masia

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dulce C Macias-CejaCIBERehd (Centro de Investigaciones en Red Enfermedad Hepática y Digestiva), Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.
Sandra CollCIBERehd (Centro de Investigaciones en Red Enfermedad Hepática y Digestiva), Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.
Cristina BausetCIBERehd (Centro de Investigaciones en Red Enfermedad Hepática y Digestiva), Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.
Marta Seco-CerveraFISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica), Hospital Dr. Peset, 46017 Valencia, Spain.ORCID 0000-0002-4278-2835
Laura Gisbert-FerrándizCIBERehd (Centro de Investigaciones en Red Enfermedad Hepática y Digestiva), Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.ORCID 0000-0002-2007-8716
Francisco NavarroServicio Cirugía y Coloproctología, Hospital de Manises, 46940 Valencia, Spain.ORCID 0000-0002-9775-3169
Jesus Cosin-RogerFISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica), Hospital Dr. Peset, 46017 Valencia, Spain.
Sara CalatayudCIBERehd (Centro de Investigaciones en Red Enfermedad Hepática y Digestiva), Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.ORCID 0000-0001-9675-2423
María D BarrachinaCIBERehd (Centro de Investigaciones en Red Enfermedad Hepática y Digestiva), Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.
Dolores Ortiz-MasiaDepartamento de Medicina, Facultad de Medicina, Universidad de Valencia, 46010 Valencia, Spain.ORCID 0000-0002-7924-9962
Universitat de València · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESHospital de Manises · ES

Funding

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas EHD19PI05CONSELLERIA D'INNOVACIO, UNISERSITATS, CIENCIA I SOCIETAT DIGITAL, GENERALITAT VALENCIANA PROMETEO 2018/141Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana UGP-19-032Ministerio de Ciencia e Innovación PID2019-108996RB-I00
6 · The paper itself

Abstract

backgroundFibrosis is a common complication of Crohn's disease (CD) in which macrophages play a central role. Epithelial-mesenchymal transition (EMT) and the WNT pathway have been associated with fibrosis. We aim to analyse the relevance of the tissue microenvironment in macrophage phenotype and the EMT process.

methodsIntestinal surgical resections are obtained from control and CD patients with stenotic or penetrating behaviour. Cytokine's expression, macrophage phenotype, EMT markers and WNT signalling pathway are determined by WB, RT-PCR, ELISA or Cytometry. U937 cells are treated with IFNγ, TNFα, IL1β, IL4 or IL10 and co-cultured with HT29 cells and, in some cases, are treated with XAV939 or

resultsIFNγ, WNT6, CD16 and CD86 are increased in the intestinal tissue of CD patients. IFNγ-treated U937 activated the EMT process and WNT pathway in HT29 cells, and the EMT process is mediated by FZD4.

conclusionsAn IFNγ-rich microenvironment polarises macrophages, which induces EMT through the WNT pathway.

Indexed as

Crohn diseaseEpithelial Mesenchymal Transition (EMT)fibrosisIFNγmacrophages

Identifiers

PMID35625832
PMCPMC9139093
OpenAlexW4229375400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.